JP2016003187A5 - - Google Patents

Download PDF

Info

Publication number
JP2016003187A5
JP2016003187A5 JP2014122464A JP2014122464A JP2016003187A5 JP 2016003187 A5 JP2016003187 A5 JP 2016003187A5 JP 2014122464 A JP2014122464 A JP 2014122464A JP 2014122464 A JP2014122464 A JP 2014122464A JP 2016003187 A5 JP2016003187 A5 JP 2016003187A5
Authority
JP
Japan
Prior art keywords
schizophrenia
bifidobacterium
therapeutic agent
active ingredient
genus bacterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014122464A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016003187A (ja
JP6234331B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2014122464A priority Critical patent/JP6234331B2/ja
Priority claimed from JP2014122464A external-priority patent/JP6234331B2/ja
Publication of JP2016003187A publication Critical patent/JP2016003187A/ja
Publication of JP2016003187A5 publication Critical patent/JP2016003187A5/ja
Application granted granted Critical
Publication of JP6234331B2 publication Critical patent/JP6234331B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014122464A 2014-06-13 2014-06-13 統合失調症治療剤 Expired - Fee Related JP6234331B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014122464A JP6234331B2 (ja) 2014-06-13 2014-06-13 統合失調症治療剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014122464A JP6234331B2 (ja) 2014-06-13 2014-06-13 統合失調症治療剤

Publications (3)

Publication Number Publication Date
JP2016003187A JP2016003187A (ja) 2016-01-12
JP2016003187A5 true JP2016003187A5 (enExample) 2016-12-28
JP6234331B2 JP6234331B2 (ja) 2017-11-22

Family

ID=55222737

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014122464A Expired - Fee Related JP6234331B2 (ja) 2014-06-13 2014-06-13 統合失調症治療剤

Country Status (1)

Country Link
JP (1) JP6234331B2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2017130859A1 (ja) * 2016-01-28 2018-11-15 森永乳業株式会社 神経細胞死抑制剤
WO2021149806A1 (en) * 2020-01-24 2021-07-29 Morinaga Milk Industry Co., Ltd. Composition for improving neurite outgrowth

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006097949A1 (en) * 2005-03-16 2006-09-21 Actial Farmacêutica, Lda. Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough
EP2110028A1 (en) * 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
US20120196803A1 (en) * 2009-06-11 2012-08-02 Angiochem Inc. Fusion proteins for delivery of gdnf and bdnf to the central nervous system
EP2308499A1 (en) * 2009-09-30 2011-04-13 Nestec S.A. Bifidobacterium longum ATCC BAA-999 (BL999) and weight control
ES2610829T3 (es) * 2009-11-11 2017-05-03 Alimentary Health Limited Cepa de Bifidobacterium
PL3072524T3 (pl) * 2010-10-07 2018-06-29 California Institute Of Technology Probiotyczne terapie dla autyzmu
JP5774517B2 (ja) * 2012-02-22 2015-09-09 森永乳業株式会社 ビフィドバクテリウム属細菌含有発酵食品の製造方法

Similar Documents

Publication Publication Date Title
WO2016086210A8 (en) Probiotic and prebiotic compositions, and methods of use thereof for treatment and prevention of graft versus host disease
MX2016014807A (es) Singenes de alfa(1,2)fucosiltransferasa para su utilizacion en la produccion de oligosacaridos fucosilados.
WO2014018596A3 (en) Alpha (1,2) fucosyltransferases suitable for use in the production of fucosylated oligosaccharides
AR110684A1 (es) Composiciones que comprenden cepas bacterianas y método de tratamiento
IL291445A (en) Bacterial strains, their compositions and their use for the treatment of gastrointestinal disorders
MY186217A (en) Mixture of hmos
CA2956871C (en) Compounds active towards bromodomains
HUE043341T2 (hu) Blautia hydrogenotrophica baktériumtörzset tartalmazó készítmények, hasmenés vagy székrekedés kezelésében vagy megelõzésében történõ alkalmazásra
WO2015114666A3 (en) Treatments for resistant acne
MX2019009132A (es) Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
MX2012002402A (es) Bifidobacterium longum y trastornos gastrointestinales funcionales.
EP3584308A3 (en) Compositions and methods
WO2015047941A3 (en) Compositions and methods for treatment and prophylaxis of gastrointestinal diseases
WO2013169864A3 (en) TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
HK1202244A1 (en) Prebiotic formulations and methods of use
WO2014180889A8 (en) Methods and compositions for the treatment of cancer
BR112017010475A2 (pt) cepas de lactobacillus ou bifidobacterium para manter homeostase
EA201992176A1 (ru) Пробиотические молекулы для снижения вирулентности патогена
WO2017022962A8 (ko) Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
EA201992175A1 (ru) Композиции и способы, включающие пробиотические молекулы
PH12016501988A1 (en) Antibacterial compounds
WO2015106215A3 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
TN2016000435A1 (en) Novel macrocyclic compounds.
WO2016057413A3 (en) Inhibitors of lysine gingipain
PH12019501439A1 (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus